Equities research analysts expect that Spark Therapeutics Inc (NASDAQ:ONCE) will report sales of $9.53 million for the current fiscal quarter, Zacks Investment Research reports. Six analysts have issued estimates for Spark Therapeutics’ earnings. The highest sales estimate is $21.30 million and the lowest is $1.50 million. Spark Therapeutics reported sales of $16.30 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 41.5%. The firm is scheduled to issue its next earnings report on Wednesday, February 28th.
On average, analysts expect that Spark Therapeutics will report full year sales of $9.53 million for the current fiscal year, with estimates ranging from $4.66 million to $25.96 million. For the next fiscal year, analysts anticipate that the business will report sales of $99.90 million per share, with estimates ranging from $32.25 million to $223.80 million. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Spark Therapeutics.
Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.11). Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The company had revenue of $1.90 million during the quarter, compared to the consensus estimate of $1.40 million. During the same period in the prior year, the company earned ($1.07) earnings per share. The firm’s revenue was up 45.8% compared to the same quarter last year.
Several research analysts have recently commented on ONCE shares. Raymond James Financial reaffirmed a “buy” rating and set a $75.00 target price on shares of Spark Therapeutics in a report on Thursday, December 7th. ValuEngine cut shares of Spark Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, November 14th. BMO Capital Markets reaffirmed a “buy” rating and set a $101.00 target price on shares of Spark Therapeutics in a report on Wednesday, November 15th. Cantor Fitzgerald set a $105.00 target price on shares of Spark Therapeutics and gave the stock a “buy” rating in a report on Tuesday, December 19th. Finally, UBS Group cut shares of Spark Therapeutics from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $92.00 to $51.00 in a report on Tuesday, December 12th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and fifteen have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $76.03.
In related news, CFO Stephen W. Webster sold 10,000 shares of the stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $70.14, for a total transaction of $701,400.00. Following the sale, the chief financial officer now owns 12,500 shares in the company, valued at approximately $876,750. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Barge Joseph La sold 5,500 shares of the stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $71.44, for a total transaction of $392,920.00. Following the sale, the insider now owns 8,146 shares in the company, valued at approximately $581,950.24. The disclosure for this sale can be found here. Insiders have sold a total of 62,309 shares of company stock worth $4,621,085 in the last quarter. 7.30% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Ameritas Investment Partners Inc. boosted its position in Spark Therapeutics by 23.6% in the second quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock valued at $122,000 after buying an additional 389 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in Spark Therapeutics in the second quarter valued at approximately $143,000. Teacher Retirement System of Texas acquired a new stake in Spark Therapeutics in the third quarter valued at approximately $225,000. Prudential Financial Inc. acquired a new stake in Spark Therapeutics in the third quarter valued at approximately $239,000. Finally, Commonwealth Equity Services Inc acquired a new stake in Spark Therapeutics in the third quarter valued at approximately $257,000. Institutional investors and hedge funds own 94.91% of the company’s stock.
Shares of Spark Therapeutics (NASDAQ ONCE) traded down $1.28 on Wednesday, hitting $50.56. 1,343,879 shares of the stock traded hands, compared to its average volume of 1,470,000. Spark Therapeutics has a 12 month low of $41.06 and a 12 month high of $91.75. The company has a market capitalization of $1,820.00 and a PE ratio of -7.02.
COPYRIGHT VIOLATION NOTICE: This piece of content was published by Equities Focus and is the property of of Equities Focus. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://www.equitiesfocus.com/2018/01/06/spark-therapeutics-inc-once-expected-to-announce-quarterly-sales-of-9-53-million.html.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Get a free copy of the Zacks research report on Spark Therapeutics (ONCE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.